In case you missed our live, online educational seminar, "Part 5: Targeting Cancer Pathways: Understanding Immune Checkpoints" we wanted to let you know that it is available in our complimentary on-demand archive.
You can access this archive to watch the webinar at any time.
For more information and access to the archive, go to:
webinar.sciencemag.org
About This Webinar
This webinar is the fifth in a series focusing on the cancer pathways that support tumor development, the emerging research in identifying and targeting these pathways, and innovations in the development of increasingly effective cancer therapy options. Recent advances in our understanding of cancer have revealed that the disease cannot be understood through simple analysis of genetic mutations within cancerous cells. Instead, tumors should be considered as complex tissues in which the cancer cells communicate directly and indirectly with the surrounding cellular microenvironment and evolve traits that promote their own survival. In this webinar, we will explore how tumors exploit immune modulatory mechanisms to generate and thrive in their own immunosuppressive microenvironment. Further, we will examine how these mechanisms can be targeted to develop better therapeutic options.
During the webinar, the speakers will:
• Provide a historical overview of immune checkpoint research and examine the effect of mutational load on clinical response
• Explain how PD-1 immunotherapy stops certain cancers from turning off the anticancer immune response
• Discuss general therapeutic approaches to activating the immune system to treat cancer
• Answer your questions live during the broadcast!
Participants:
James P. Allison, Ph.D.
MD Anderson Cancer Center
Houston, TX
Gordon J. Freeman, Ph.D.
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA
Philip J. Gotwals, Ph.D.
Novartis Institutes for BioMedical Research
Cambridge, MA
Register at:
webinar.sciencemag.org
No comments:
Post a Comment